Cutaneous lymphoma research and clinical trials

 
Cutaneous lymphoma research at City of Hope is focused on developing and discovering new treatments to improve prognosis and outcomes for our patients. Clinical investigations we are leading include efforts to better understand the tumor microenvironment — the interaction between tumor and other cells that foster cancer growth — and finding new targets and developing new therapies aimed at finding a cure. We are testing dozens of new therapies and combinations for lymphoma patients developed and manufactured in City of Hope’s own on-campus labs.
 
Our current open trials include:
 
IRB 15157: A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor®.
 
PHASE I

IRB 16273: A Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides.

IRB 15270: A Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type.
 
IRB 15165: A Study Evaluating Safety, Tolerability, and Pharmakinetics of Escalating Doses or AGS67E Given as Monotherapy in Subjects with Refractory or Relapsed Lymphoid Malignancies.

IRB 14349: A Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients with Mature T-Cell Non-Hodgkin Lymphoma: the aTAC-BEAM Regimen.
 
PHASE I / IIA
 
IRB 16221: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

IRB 16257: An Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors of Lymphomas Expressing Wild-Type p53 Protein.
 
PHASE I / IB

IRB 15428: A Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual P13K Delta/Gamma Inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma.
 
PHASE II

IRB 16042: A Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL).

IRB 14321: A Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL).

IRB 14290: A Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL
 
 
PHASE III

IRB 15122: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma.
        
IRB 14338: A Randomized, Double-Blind, Placebo-Controlled Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas.
 
For more information on a specific clinical trial, please call 626-218-1133. For a full listing of clinical trials, visit clinicaltrials.coh.org.